Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, December 9 at 2:00 PM ET

Register Free →

Clinical Trial Statistical Support

Open
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Place of Performance

Durham, NC, 27713, USA

Set-Aside

NONE

Documents

This scope was carved out of 75N93026R00009.

The full solicitation package (1 document), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

AUTOIMMUNE DISEASES STATISTICAL & CLINICAL COORDINATING CENTER (AD-SCCC)

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Due in 15 days

Read the full solicitation package

This scope is part of a larger contract. Its documents live on the prime.

  • 1 document on the prime contractFrom AUTOIMMUNE DISEASES STATISTICAL & CLINICAL COORDINATING CENTER (AD-SCCC)
Read the prime's documents

Ask CLEATUS

I've read this contract. Ask me anything.

Timeline

Posted

subcontract

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Niaid
ContactsNo contacts available
OfficeN/A
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Performs statistical design, power calculations, and data analysis for prime contractors on NIAID autoimmune disease and mucosal immunology clinical research projects. Develops statistical analysis plans (SAPs) and executes data analysis for Autoimmunity Centers of Excellence (ACE) and investigator-initiated clinical trials (IICT). Requires expertise in clinical trial statistics and NIAID research standards. Delivers statistical analysis reports, validated data sets, and protocol design documents.

Similar Contracts

Same NAICS industry code

NAICS: 541715
New
SBIR / STTR
Ground-Based Affordable Mass (G-BAM)
Solicitation # ARM26BX04-DV010
The Ground-Based Affordable Mass (G-BAM) solicitation, issued by the U.S. Army under the U.S. Department of Defense, is a total small business set-aside opportunity utilizing a direct-to-Phase II SBIR structure. The program is designed as a three-phased effort, where Phase I typically lasts six to twelve months and Phase II generally spans 24 months. Proposals are submitted via the DSIP portal and must be organized into seven specific volumes, including technical, cost, and commercialization reports. Technical proposals must adhere to strict formatting guidelines, including a single PDF format, one-inch margins, and a minimum 10-point font, with a risk of rejection if page limits are exceeded. Award selections are based on the overall technical value and cost, with a primary focus on technical capability, innovation, and the qualifications of key personnel. Evaluation factors are prioritized by the soundness of the technical approach, the ability of the team to perform R&D and commercialize results, and the overall commercial potential for government or private sector application. To be eligible, proposing entities must be registered in the System for Award Management (SAM) and the SBA Company Registry. Additionally, contractors must comply with stringent security and legal requirements, including the Cybersecurity Maturity Model Certification (CMMC) program, Foreign Risk Evaluation (FRE), and the disclosure of any organizational conflicts of interest.
U.S. Army

POSTED

about 10 hours ago

DEADLINE

in 14 days
View Details
NAICS: 541715
New
Federal
UNITED STATES ARMY RESEARCH INSTITUTE FOR THE BEHAVIORAL AND SOCIAL SCIENCES (ARI) BROAD AGENCY ANNOUNCEMENT FOR BASIC, APPLIED, AND ADVANCED SCIENTIFIC RESEARCH
Solicitation # W911NF-23-S-0010
Broad Agency Announcement W911NF-23-S-0010 is a multi-year solicitation issued by the United States Army Research Institute for the Behavioral and Social Sciences (ARI) to acquire basic, applied, and advanced scientific research. Valid from May 1, 2023, to April 30, 2028, the BAA focuses on enhancing Army readiness and performance through the behavioral and social sciences. Key research areas include holistic personnel assessment, job classification and assignment, leadership development for organizational and strategic leaders, team composition and effectiveness in future operational environments, and the assessment of technological fluency. The acquisition process typically follows a three-step sequence: initial contact with an ARI Technical Point of Contact, submission of a white paper (limited to six pages), and a subsequent full proposal if encouraged. Proposals are evaluated based on scientific and technical merit, potential contribution to the ARI mission, qualifications of key personnel, and cost, with technical merit weighted most heavily. Award instruments may include contracts or grants, with specific project budgets ranging from approximately 320,000 dollars for creative performance research to 1.35 million dollars for career progression studies. Administrative requirements include registration in the System for Award Management and the provision of CAGE codes and Taxpayer Identification Numbers. Proposals must adhere to strict formatting guidelines, including a 23-page limit for core technical sections. Special provisions are in place regarding Organizational Conflicts of Interest, particularly for entities with existing Intergovernmental Personnel Act agreements, and strict prohibitions against including classified information in white papers.
W6QK Acc-Apg Durham

POSTED

about 11 hours ago

DEADLINE

in over 1 year
View Details
NAICS: 541715
New
Federal
Notice of Intent (NOI) to Sole Source proprietary prodrug MP201 to ISB for testing Acute Stress Reactions (ASRs)
Solicitation # HT9426-27-NOI-049825
The Defense Health Agency, on behalf of the Walter Reed Army Institute of Research, has issued a Notice of Intent to sole source the procurement of the proprietary prodrug MP201 to the Integrative Systems Biology (ISB) Branch. The primary objective is to support the testing of Acute Stress Reactions (ASRs). The scope of work requires the contractor to supply two freshly made batches of MP201 synthesized for oral administration in mice, with target dosages ranging approximately from 8 to 80 mg/kg body weight. In addition to the physical product, the contractor must provide quality control documentation, dosage background information, and technical support to assist the ISB research team in preparing related reports and manuscripts. This action is identified by solicitation number HT9426-27-NOI-049825 and is categorized under NAICS code 541715. As this is a Notice of Intent and not a request for competitive proposals, no formal solicitation document or pricing data is currently available. Interested parties must submit capability statements in writing via PDF, MS Word, or Excel to Herbert Keen or Lance Nowell by 2:00 p.m. Eastern Time on December 31, 2026. All submissions must be unclassified, as the agency has explicitly stated that classified material should not be submitted.
Defense Health Agency

POSTED

about 11 hours ago

DEADLINE

in about 1 month
View Details
NAICS: 541715
New
Federal
AUTOIMMUNE DISEASES STATISTICAL & CLINICAL COORDINATING CENTER (AD-SCCC)
Solicitation # 75N93026R00009
The National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health (NIH) is seeking to extend the contract for the Autoimmune Diseases Statistical and Clinical Coordinating Center (AD-SCCC). This project provides essential support for the design, development, execution, and analysis of clinical research focused on autoimmune diseases, mucosal immunology, and primary immune deficiencies. The scope of work includes supporting the Autoimmunity Centers of Excellence and Immune Tolerance Network (ACE) and investigator-initiated clinical trials (IICT). Key responsibilities encompass statistical design and analysis, protocol development, data management, clinical safety and pharmacovigilance support, and the management of biological specimen repositories and collaboration portals. The NIAID intends to negotiate a sole source modification with Rho Federal Systems Division, Inc. under FAR Part 6.302-1 and HHSAR Part 306.302-1 to avoid significant disruptions to critical services and ensure participant safety and data integrity. The proposed 18-month extension is structured as two discrete option periods: a 12-month period from February 1, 2027, through January 31, 2028, and a 6-month period through July 31, 2028. This extension maintains the existing term type/level of effort contract structure and scope to ensure continuity of operations while the agency completes a separate competition process.
National Institutes Of Health Niaid

POSTED

about 11 hours ago

DEADLINE

in 15 days
View Details
NAICS: 541715
New
Federal
Office of Hazardous Materials Safety Research Initiative – FY2026 BROAD AGENCY ANNOUNCEMENT (BAA)
Solicitation # PHMSA-26HM-BAA
The U.S. Department of Transportation's Pipeline and Hazardous Materials Safety Administration (PHMSA) is soliciting research proposals under Broad Agency Announcement PHMSA-26HM-BAA to advance safety and prevent incidents during the transportation of hazardous materials. The initiative focuses on five core topic areas: Efficient Safety Standards (26HM-ESS), Safe Energy Storage Technologies (26HM-SST), Innovative Packaging (26HM-IPG), Risk Reduction for Emergency Response (26HM-RER), and Hazardous Materials Rail Transportation Safety (26HM-RTS). Eligible applicants include U.S.-based industry, accredited universities, non-profits, and permitted federally affiliated research centers, while foreign entities may only participate as subcontractors. The selection process consists of two phases, beginning with a Phase I white paper due November 18, 2026, followed by invited Phase II full proposals. Awards will be issued as Firm-Fixed-Price or Cost-Reimbursement procurement contracts with a ceiling of $2,000,000 per independent submission and a performance period of up to 36 months. Evaluation for Phase I is based on technical merit and feasibility (35%), relevance to program mission (35%), experience and qualifications (20%), and submission quality (10%). Phase II adds cost realism as a weighted factor. Awarded contractors must provide regular progress reports, a data management plan, and a plain-language project one-pager.
693JK3 Acquisition Services Division

POSTED

about 11 hours ago

DEADLINE

in 1 day
View Details

More opportunities from Department Of Health And Human Services → National Institutes Of Health Niaid

Same awarding agency

NAICS: 541715
Federal
2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases
Solicitation # HHS-NIH-NIAID-BAA2026-1
The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting proposals under Broad Agency Announcement HHS-NIH-NIAID-BAA2026-1 to advance medical interventions for infectious diseases. The initiative focuses on three primary research areas: the development of needle-free vaccine candidates through early phase clinical trials for viral pathogens; the creation of safe and effective therapeutic products for serious infectious diseases that are currently untreatable or drug-resistant; and the innovation of in vitro diagnostic technology platforms capable of rapid, point-of-care detection of priority viral families. For Fiscal Year 2027, NIAID estimates a total award amount of up to 16 million dollars for the non-severable base awards, with the potential for cost-reimbursement contracts lasting up to five years. Proposals must be submitted electronically via the eCPS portal by December 8, 2026, at 3:00 PM Eastern Time. Technical proposals are limited to 75 pages and will be evaluated by a peer review group based on scientific and technical merit, which is the paramount consideration for award. While cost is a factor, it is significantly less important than technical acceptability. Awardees will be required to adhere to Good Manufacturing Practice (GMP) for drug products and comply with HHS Section 508 accessibility standards. Key personnel must be named in the award, and a mandatory kick-off meeting is required within 60 days of the effective award date.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

12 days ago

DEADLINE

in 22 days
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS